Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junya Kanda

Showing results (361-370 of 390) with videos related to

Pageof 39
Sort By:
Therapeutic Advances in Hematology|July 5, 2022
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisYoshiyuki Onda, Junya Kanda, Hitomi Kaneko, et al.
Leukemia|August 15, 2019
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative studyJunya Kanda, Hiromi Hayashi, Annalisa Ruggeri, et al.
American Journal of Hematology|September 26, 2025
Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in AdultsMasatoshi Sakurai, Keisuke Kataoka, Kota Mizuno, et al.
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
Hematological Oncology|March 16, 2021
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myelomaTeruhito Takakuwa, Kensuke Ohta, Eiji Nakatani, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
Hematology (Amsterdam, Netherlands)|February 14, 2022
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trialHiroyuki Muranushi, Junya Kanda, Masayuki Kobayashi, et al.
Blood Advances|December 15, 2023
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and JapanMizuki Watanabe, Junya Kanda, Fernanda Volt, et al.
International Journal of Hematology|September 22, 2020
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registryAya Nakaya, Takae Kohara, Hirohiko Shibayama, et al.
International Journal of Hematology|August 13, 2020
Retrospective analysis of plasmacytoma in Kansai Myeloma Forum RegistryAya Nakaya, Hirokazu Tanaka, Hideo Yagi, et al.
Pageof 39

Showing results (361-370 of 390) with videos related to

Sort By:
Pageof 39
Therapeutic Advances in Hematology|July 5, 2022
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisYoshiyuki Onda, Junya Kanda, Hitomi Kaneko, et al.
Leukemia|August 15, 2019
Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative studyJunya Kanda, Hiromi Hayashi, Annalisa Ruggeri, et al.
American Journal of Hematology|September 26, 2025
Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in AdultsMasatoshi Sakurai, Keisuke Kataoka, Kota Mizuno, et al.
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
Hematological Oncology|March 16, 2021
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myelomaTeruhito Takakuwa, Kensuke Ohta, Eiji Nakatani, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
Hematology (Amsterdam, Netherlands)|February 14, 2022
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trialHiroyuki Muranushi, Junya Kanda, Masayuki Kobayashi, et al.
Blood Advances|December 15, 2023
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and JapanMizuki Watanabe, Junya Kanda, Fernanda Volt, et al.
International Journal of Hematology|September 22, 2020
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registryAya Nakaya, Takae Kohara, Hirohiko Shibayama, et al.
International Journal of Hematology|August 13, 2020
Retrospective analysis of plasmacytoma in Kansai Myeloma Forum RegistryAya Nakaya, Hirokazu Tanaka, Hideo Yagi, et al.
Pageof 39